恩度联合化疗治疗117例晚期恶性肿瘤(英文)

Objective: The aim of this study was to evaluate the recent efficacy and adverse reactions of recombinant human endostatin (Endostar) plus chemotherapy in the treatment of advanced malignancies. Methods: One hundred and seventeen cases of advanced malignancies were diagnosed and confirmed by histopathological examination, patients were treated with Endostar combined with chemotherapeutic drugs with no cross-resistance. Evaluate the efficacy and adverse reactions after finished two cycles of combination therapy. Results: All the 117 cases of patients were evaluated according to relevant standards, and there were 12 cases of complete remission (CR), 30 cases of partial remission (PR), 58 cases of stable disease (SD), 17 cases of progressive disease (PD). The response rate (RR) was 35.8%, disease control rate (DCR) was 85.4%. Conclusion: The protocol of Endostar combined with chemotherapy could improve the quality of life of patients with malignances, it also has the advantage of low toxicity. Considering the time span of the study, the long-term efficacy remains to be observed.

多西他赛联合同步放疗治疗晚期鼻咽癌的临床研究(英文)

Objective:The aim of this study was to study the short-term curative effects and adverse reactions of docetaxel(DOC) in concurrent chemoradiotherapy compared to DDP plus 5-Fu(DF) combined with concurrent radiotherapy in patients with advanced nasopharyngeal carcinoma.Methods:Thirty-three patients in the experimental group(DOC group) were given DOC 25 mg/m 2 ivgtt,d1,7 times,concurrent radiotherapy was performed from d1.Thirty-three patients in the control group(DF group) were given cisplatin 25 mg/m 2 ivgtt d1–3 and 5-Fu 550 mg/m 2 iv,d1–5,3 weeks a cycle,2 cycles,and concurrent radiotherapy was performed from d1.Six MV X-ray and 9 MeV electronic line for external irradiation were adopted in concurrent radiotherapy.Results:The response rates of DOC group and DF group were 90.9% and 93.9%,the rates of neutropenia were 45.45% and 67.74%,and the rates of oral mucositis were 60.61% and 90.32%.Conclusion:The difference of shortterm curative effects between DOC group and DF group was not statistically significant in patients with advanced nasopharyngeal carcinoma.The rates of adverse reactions were lower in DOC group.DOC combined with concurrent radiotherapy could be a new choice for patients with advanced nasopharyngeal carcinoma.

含铂方案同步三维适形放疗治疗局部晚期非小细胞肺癌78例临床观察(英文)

Objective: The aim of our study was to explore the short-term efficacy of platinum-based combined with concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer(NSCLC). Methods: Between 2006 to 2010, 78 cases of locally advanced NSCLC were enrolled into this trial. All patients were given platinum-based chemotherapy combined with concurrent three-dimensional conformal radiotherapy(3-DCRT). Chest CT scans were obtained during end-expiratory and end-inspiratory pauses when performing positioning. Image fusion was done after the image data was transferred to treatment plan system(TPS). The target volume was delineated on the fusion images. The chemotherapy was given on the first day of radiotherapy. Comprehensive examinations were conducted 4–6 weeks after concurrent chemoradiotherapy to assess short-term efficacy. Results: Complete remission(CR) was achieved in 8 cases and partial remission(PR) in 54 cases. The efficiency rate reached 79.5%. Grade III–IV radiation esophagitis occurred in 11.5%. No exit and death cases during treatment. Conclusion: Concurrent chemo-radiotherapy could significantly improve the short-term efficacy and prolong survival of stage III NSCLC, meanwhile the adverse reactions could be tolerated.

金水鲜联合放疗对肺腺癌A549细胞增殖及VEGF表达的影响(英文)

Objective:The aim of our study was to investigate whether Jinshuixian has the abilities of inhibiting tumor growth and radio-sensitivity effect.Methods:Cultured lung A549 cells were randomly divided into 6 groups:normal control group(NC),the Jinshuixian group(JSX),radiotherapy(RT),JSX for the first day and the next day followed by RT group(JSX→RT),RT for the first day and the next day followed by JSX group(RT→JSX)and RT+JSX concomitantly group(JSX+RT).MTT was applied to measure the cell viability,RT-PCR and ELISA were used to test the expression of mRNA and protein of VEGF.Results:The proliferation of A549 cells were inhibited in JSX and combined groups and the inhibiting effects were time dependent.The expression of VEGF in RT group was increased,however,VEGF in JSX and combination groups were largely decreased over time when compared to NC group.Results in JSX→RT,RT→JSX and JSX+RT groups did not achieve significantly differences.Conclusion:JSX has the ability of anti-tumor growth in vitro accompanied down-regulating of VEGF,especially when combined with radiotherapy,and its effect is time-dependent.However,more studies in vivo and in vitro are needed to further supporting these effects.

恩度通过抑制肺腺癌A549细胞HIF-1α及bFGF表达提高放疗疗效(英文)

Objective:The aim of the study was to investigate whether enhanced anti-tumor effects of endostar(ES) on radiation involved hypoxia inducible factor-1α(HIF-1α) and basic fibroblast growth factor(bFGF).Methods:A549 cells were divided into four groups:control group;endostar(ES) group;radiation(RT) group;endostar plus radiation(ES + RT) group.The inhibition of proliferation rates of A549 cells was measured by cell counting kit-8(CCK-8).HIF-1α and bFGF expression levels were checked by enzyme linked immunosorbent assay(ELISA) and reverse transcription-polymerase chain reaction(RT-PCR).Results:The proliferation inhibition rate in the ES + RT group was higher than that in other groups.On the other hand,the expressions of HIF-1α and bFGF in the ES + RT group were significantly reduced compared to other groups.HIF-1α and bFGF levels were positively correlated(r=0.80,P<0.01).Conclusion:Our results suggest that endostar could enhance anti-tumor effect of radiation by reducing expressions of HIF-1α and bFGF.